


# Key Stakeholders in the AMR Ecosystem Aim to Address Market Failures and Catalyze Investment in Early- and Late-Stage Research to Ensure New Antimicrobials Reach Patients

Without a commercially viable antimicrobial market, many small, start-up biotech companies often struggle to find the financing to overcome the pre-clinical stages of development known as the “valley of death,” where many projects are abandoned due to lack of funding. Even among those that surpass this hurdle and make it into clinical testing, many struggle to find financing or broker acquisition by a larger pharmaceutical company in order to bring a drug to market. A unique biopharmaceutical ecosystem has evolved to address these challenges. Policy reforms are needed to ensure a sustainable market for antimicrobials once they are approved.



**Citation:** Adapted from CARB-X and Payne DJ et al., *Drugs for bad bugs: confronting the challenges of antibacterial discovery*. *Nat Rev Drug Discov.* 2007;6(1):29-40; Czaplewski L et al. *Alternatives to antibiotics-a pipeline review*. *Lancet Infectious Dis.* 2016(2): 239-51.

**Combatting Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X):** CARB-X is a global non-profit partnership among academia, charitable foundations, NIH and global partners dedicated to advancing AMR research by accelerating pre-clinical candidates toward clinical development.

**AMR Action Fund:** The AMR Action Fund is a broad alliance setup by the biopharmaceutical industry that offers a bridging solution for biotechnology companies in the late stages of development of antimicrobial medicines and funding to help get over the finish line.

**Glossary:** IND: Investigational New Drug Application      NDA: New Drug Application      BLA: Biologic Drug Application